Laboratorios Farmaceuticos ROVI Total Liabilities
Laboratorios Farmaceuticos ROVI total liabilities. Based on the latest financial reports, Laboratorios Farmaceuticos ROVI (ROVI) has total liabilities worth €289.27 Million EUR (≈ $338.18 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Laboratorios Farmaceuticos ROVI liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Laboratorios Farmaceuticos ROVI (2003–2024)
Total liabilities of Laboratorios Farmaceuticos ROVI from 2003 to 2024. This chart illustrates how Laboratorios Farmaceuticos ROVI's total liabilities have evolved over time, based on quarterly financial data. Explore ROVI strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Laboratorios Farmaceuticos ROVI Competitors by Total Liabilities
The table below lists competitors of Laboratorios Farmaceuticos ROVI ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Baic Bluepark New Energy Technology
SHG:600733
|
China | CN¥28.37 Billion |
|
DMG MORI AKTIENGESELLSCHAFT
XETRA:GIL
|
Germany | €1.06 Billion |
|
Kulicke and Soffa Industries Inc
F:KU1
|
Germany | €407.13 Million |
|
Indofood Cbp Sukses Makmur Tbk
JK:ICBP
|
Indonesia | Rp61.06 Trillion |
|
Figure Technology Solutions, Inc. Class A Common Stock
NASDAQ:FIGR
|
USA | $980.23 Million |
|
Kontoor Brands Inc
NYSE:KTB
|
USA | $2.33 Billion |
|
Dairy Farm International Holdings Limited
F:DFA1
|
Germany | €4.29 Billion |
|
Pampa Energía S.A
F:9PAA
|
Germany | €3.23 Billion |
Liability Composition Analysis (2003–2024)
This chart breaks down Laboratorios Farmaceuticos ROVI's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ROVI current and non-current assets.
Liquidity & Leverage Metrics
Laboratorios Farmaceuticos ROVI Total Liabilities Ratios Explained
Laboratorios Farmaceuticos ROVI total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Laboratorios Farmaceuticos ROVI's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Laboratorios Farmaceuticos ROVI (2003–2024)
The table below shows the annual total liabilities of Laboratorios Farmaceuticos ROVI from 2003 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €250.48 Million ≈ $292.84 Million |
-2.30% |
| 2023-12-31 | €256.39 Million ≈ $299.75 Million |
-28.25% |
| 2022-12-31 | €357.32 Million ≈ $417.75 Million |
+36.54% |
| 2021-12-31 | €261.70 Million ≈ $305.95 Million |
+30.37% |
| 2020-12-31 | €200.74 Million ≈ $234.68 Million |
+6.31% |
| 2019-12-31 | €188.82 Million ≈ $220.76 Million |
+63.87% |
| 2018-12-31 | €115.23 Million ≈ $134.71 Million |
+8.00% |
| 2017-12-31 | €106.69 Million ≈ $124.74 Million |
+2.16% |
| 2016-12-31 | €104.44 Million ≈ $122.10 Million |
+5.43% |
| 2015-12-31 | €99.06 Million ≈ $115.81 Million |
-3.68% |
| 2014-12-31 | €102.85 Million ≈ $120.24 Million |
+12.45% |
| 2013-12-31 | €91.46 Million ≈ $106.93 Million |
-4.65% |
| 2012-12-31 | €95.92 Million ≈ $112.14 Million |
-15.93% |
| 2011-12-31 | €114.09 Million ≈ $133.38 Million |
+4.90% |
| 2010-12-31 | €108.75 Million ≈ $127.14 Million |
+15.18% |
| 2009-12-31 | €94.42 Million ≈ $110.39 Million |
+30.94% |
| 2008-12-31 | €72.11 Million ≈ $84.30 Million |
+19.71% |
| 2007-12-31 | €60.23 Million ≈ $70.42 Million |
+19.92% |
| 2006-12-31 | €50.23 Million ≈ $58.72 Million |
-100.00% |
| 2005-12-31 | €3.35 Trillion ≈ $3.92 Trillion |
+42431.24% |
| 2004-12-31 | €7.88 Billion ≈ $9.21 Billion |
+25477.80% |
| 2003-12-31 | €30.80 Million ≈ $36.00 Million |
-- |
About Laboratorios Farmaceuticos ROVI
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Trypti… Read more